2,039 results on '"Bu, B"'
Search Results
2. Predictive Factors for Poor Outcomes Associated with COVID-19 in a Retrospective Cohort of Myasthenia Gravis Patients
- Author
-
Bi Z, Gao H, Lin J, Gui M, Li Y, Li Z, and Bu B
- Subjects
myasthenia gravis ,covid‐19 ,poor outcomes ,immunosuppressive treatment ,immune responses. ,Pathology ,RB1-214 ,Therapeutics. Pharmacology ,RM1-950 - Abstract
Zhuajin Bi,1,2 Huajie Gao,1,2 Jing Lin,1,2 Mengcui Gui,1,2 Yue Li,1,2 Zhijun Li,1,2 Bitao Bu1,2 1Department of Neurology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei Province, People’s Republic of China; 2Hubei Key Laboratory of Neural Injury and Functional Reconstruction, Huazhong University of Science and Technology, Wuhan, People’s Republic of ChinaCorrespondence: Zhijun Li, Department of Neurology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei Province, People’s Republic of China, Email lizhijun@tjh.tjmu.edu.cn Bitao Bu, Email bubitao@tjh.tjmu.edu.cnPurpose: To investigate the predictors for poor outcomes (including disease exacerbation, hospitalization and myasthenic crisis) in patients with pre-existing myasthenia gravis (MG) following Coronavirus disease 2019 (COVID-19), and to explore the potential effects of COVID-19 on inflammatory and immune responses in MG patients.Patients and Methods: This retrospective cohort study analyzed medical records of 845 MG patients who were diagnosed with COVID-19 between January 2020 to March 2023 at a single medical center.Results: Generalized MG at onset and comorbidities (chronic kidney disease and malignancy) were independent risk factors of poor outcomes. Patients achieving minimal manifestation or better status before COVID-19 had a significantly reduced risk for poor outcomes. Furthermore, patients with older onset age or anti-acetylcholine receptor antibody had a higher risk of exacerbation and hospitalization than those without. Prednisone or immunosuppressant treatment had the potential to reduce the occurrence of poor outcomes, while the duration of prednisone or immunosuppressant usage was associated with a higher risk of poor outcomes. Of the 376 MG patients with blood results available, patients with COVID-19 tended to have higher levels of leukocyte counts, neutrophil-lymphocyte-ratio, hypersensitive C-reactive protein, and Interleukin-6, as well as lower percentages of lymphocytes and regulatory T cells compared to patients without COVID-19.Conclusion: Disease severity at onset, comorbidities, and unsatisfactory control of myasthenic symptoms predicted the occurrence of poor outcomes in MG patients following COVID-19. The risk of poor outcomes was reduced in patients controlled by short-term immunosuppressive therapy. Novel coronavirus might affect inflammatory and immune responses in MG patients, particularly in altering interleukin-6 and regulatory T cell levels.Keywords: myasthenia gravis, COVID‐19, poor outcomes, immunosuppressive treatment, immune responses
- Published
- 2024
3. Beyond T-Trials, T4DM and TRAVERSE: the next large testosterone randomized controlled trial
- Author
-
Yeap, Bu B., Tran, Cammie, Douglass, Catherine M., and McNeil, John J.
- Published
- 2024
- Full Text
- View/download PDF
4. Comparing the Impacts of Testosterone and Exercise on Lean Body Mass, Strength and Aerobic Fitness in Aging Men
- Author
-
Daniel J. Green, Lauren C. Chasland, Bu B. Yeap, and Louise H. Naylor
- Subjects
Skeletal muscle ,Function ,Anabolic ,Body composition ,Oxygen uptake ,Sports medicine ,RC1200-1245 - Abstract
Abstract Background Based on the largely untested premise that it is a restorative hormone that may reverse the detrimental impacts of aging, prescription of testosterone (T) has increased in recent decades despite no new clinical indications. It is apparent that middle-aged and older men with low-normal serum T levels are considering T supplementation as an anti-aging strategy. At the same time, there is evidence that physical activity (PA) is at historical lows in the Western world. In this review, we compare the impacts of T treatment aimed at achieving physiological T concentrations in middle-aged and older men, alongside the impacts of ecologically relevant forms of exercise training. The independent, and possible combined, effects of T and exercise therapy on physiological outcomes such as aerobic fitness, body composition and muscular strength are addressed. Main Body Our findings suggest that both T treatment and exercise improve lean body mass in healthy older men. If improvement in lean body mass is the primary aim, then T treatment could be considered, and the combination of T and exercise may be more beneficial than either in isolation. In terms of muscle strength in older age, an exercise program is likely to be more beneficial than T treatment (where the dose is aimed at achieving physiological concentrations), and the addition of such T treatment does not provide further benefit beyond that of exercise alone. For aerobic fitness, T at doses aimed at achieving physiological concentrations has relatively modest impacts, particularly in comparison to exercise training, and there is limited evidence as to additive effects. Whilst higher doses of T, particularly by intramuscular injection, may have larger impacts on lean body mass and strength, this must be balanced against potential risks. Conclusion Knowing the impacts of T treatment and exercise on variables such as body composition, strength and aerobic fitness extends our understanding of the relative benefits of physiological and pharmacological interventions in aging men. Our review suggests that T has impacts on strength, body composition and aerobic fitness outcomes that are dependent upon dose, route of administration, and formulation. T treatment aimed at achieving physiological T concentrations in middle-aged and older men can improve lean body mass, whilst exercise training enhances lean body mass, aerobic fitness and strength. Men who are physically able to exercise safely should be encouraged to do so, not only in terms of building lean body mass, strength and aerobic fitness, but for the myriad health benefits that exercise training confers.
- Published
- 2024
- Full Text
- View/download PDF
5. Balance and strength measures are associated with incident dementia in older men
- Author
-
Jack Paterson, Michelle Trevenen, Keith Hill, Osvaldo P. Almeida, Bu B. Yeap, Jonathan Golledge, Graeme J. Hankey, and Leon Flicker
- Subjects
Physical performance ,Dementia ,Cognitive impairment ,Balance ,Strength ,Geriatrics ,RC952-954.6 - Abstract
Background: As people age the risk of dementia increases. Balance and strength deteriorate with ageing, but their associations with dementia are not clear. We aimed to determine relationships of balance and strength performance with incident dementia in the Health in Men Study (HIMS) cohort. Methods: We used wave 4 of the HIMS as baseline for analyses (2011–2013), following 1261 men until December 2017 via data linkage to determine incident dementia. Balance was measured using a modified Balance Outcome Measure for Elder Rehabilitation (mBOOMER) Score and strength with the knee extension test. Cox proportional hazards regression was used, adjusting for sociodemographic and health data. Strength and balance scores were analysed non-linearly using restricted cubic splines. Results: 13.7% of men were diagnosed with dementia over a mean period of 4.7 (SD 1.5) years. Higher baseline mBOOMER scores were associated with a reduced risk of incident dementia, with greater changes in risk at higher mBOOMER scores (9 vs 8: HR 0.80, 95% CI 0.73–0.88; 12 vs 11: 0.49, 95% HR 0.36–0.68). Higher baseline lower limb strength was associated with a reduced risk of incident dementia, with greater changes occurring at lower scores, plateauing at around 25 kg (5 vs 4: HR 0.93, 95% CI 0.89–0.98; 25 vs 24: HR 0.99, 95% CI 0.95–1.03). Conclusions: This study demonstrated a non-linear association of better performance in both strength and balance with reduced likelihood of incident dementia. These results raise the hypothesis that strategies to improve strength and balance could reduce the incidence of dementia in older men.
- Published
- 2024
- Full Text
- View/download PDF
6. Subclinical thyroid dysfunction and incident diabetes: a systematic review and an individual participant data analysis of prospective cohort studies
- Author
-
Alwan, Heba, Villoz, Fanny, Feller, Martin, Dullaart, Robin PF, Bakker, Stephan JL, Peeters, Robin P, Kavousi, Maryam, Bauer, Douglas C, Cappola, Anne R, Yeap, Bu B, Walsh, John P, Brown, Suzanne J, Ceresini, Graziano, Ferrucci, Luigi, Gussekloo, Jacobijn, Trompet, Stella, Iacoviello, Massimo, Moon, Jae Hoon, Razvi, Salman, Bensenor, Isabela M, Azizi, Fereidoun, Amouzegar, Atieh, Valdés, Sergio, Colomo, Natalia, Wareham, Nick J, Jukema, J Wouter, Westendorp, Rudi GJ, Kim, Ki Woong, Rodondi, Nicolas, Del Giovane, Cinzia, and Collaboration, for the Thyroid Studies
- Subjects
Biomedical and Clinical Sciences ,Clinical Sciences ,Prevention ,Diabetes ,Clinical Research ,Detection ,screening and diagnosis ,4.2 Evaluation of markers and technologies ,Metabolic and endocrine ,Adult ,Cohort Studies ,Data Analysis ,Diabetes Mellitus ,Female ,Humans ,Hyperthyroidism ,Hypothyroidism ,Male ,Middle Aged ,Prospective Studies ,Thyroid Diseases ,Thyrotropin ,Paediatrics and Reproductive Medicine ,Endocrinology & Metabolism ,Clinical sciences ,Reproductive medicine - Abstract
ObjectiveFew prospective studies have assessed whether individuals with subclinical thyroid dysfunction are more likely to develop diabetes, with conflicting results. In this study, we conducted a systematic review of the literature and an individual participant data analysis of multiple prospective cohorts to investigate the association between subclinical thyroid dysfunction and incident diabetes.MethodsWe performed a systematic review of the literature in Medline, Embase, and the Cochrane Library from inception to February 11, 2022. A two-stage individual participant data analysis was conducted to compare participants with subclinical hypothyroidism and subclinical hyperthyroidism vs euthyroidism at baseline and the adjusted risk of developing diabetes at follow-up.ResultsAmong 61 178 adults from 18 studies, 49% were females, mean age was 58 years, and mean follow-up time was 8.2 years. At the last available follow-up, there was no association between subclinical hypothyroidism and incidence of diabetes (odds ratio (OR) = 1.02, 95% CI: 0.88-1.17, I2 = 0%) or subclinical hyperthyroidism and incidence of diabetes (OR = 1.03, 95% CI: 0.82-1.30, I2 = 0%), in age- and sex-adjusted analyses. Time-to-event analysis showed similar results (hazard ratio for subclinical hypothyroidism: 0.98, 95% CI: 0.87-1.11; hazard ratio for subclinical hyperthyroidism: 1.07, 95% CI: 0.88-1.29). The results were robust in all sub-group and sensitivity analyses.ConclusionsThis is the largest systematic review and individual participant data analysis to date investigating the prospective association between subclinical thyroid dysfunction and diabetes. We did not find an association between subclinical thyroid dysfunction and incident diabetes. Our results do not support screening patients with subclinical thyroid dysfunction for diabetes.Significance statementEvidence is conflicting regarding whether an association exists between subclinical thyroid dysfunction and incident diabetes. We therefore aimed to investigate whether individuals with subclinical thyroid dysfunction are more prone to develop diabetes in the long run as compared to euthyroid individuals. We included data from 18 international cohort studies with 61 178 adults and a mean follow-up time of 8.2 years. We did not find an association between subclinical hypothyroidism or subclinical hyperthyroidism at baseline and incident diabetes at follow-up. Our results have clinical implications as they neither support screening patients with subclinical thyroid dysfunction for diabetes nor treating them in the hope of preventing diabetes in the future.
- Published
- 2022
7. The role of bone in energy metabolism: A focus on osteocalcin
- Author
-
Smith, Cassandra, Lin, Xuzhu, Parker, Lewan, Yeap, Bu B., Hayes, Alan, and Levinger, Itamar
- Published
- 2024
- Full Text
- View/download PDF
8. Exposure to low-level ambient air pollution and the relationship with lung and bladder cancer in older men, in Perth, Western Australia
- Author
-
Lim, Elizabeth H., Franklin, Peter, Trevenen, Michelle L., Nieuwenhuijsen, Mark, Yeap, Bu B., Almeida, Osvaldo P., Hankey, Graeme J., Golledge, Jonathan, Etherton-Beer, Christopher, Flicker, Leon, Robinson, Suzanne, and Heyworth, Jane
- Published
- 2023
- Full Text
- View/download PDF
9. Balance and strength measures are associated with incident dementia in older men
- Author
-
Paterson, Jack, Trevenen, Michelle, Hill, Keith, Almeida, Osvaldo P., Yeap, Bu B., Golledge, Jonathan, Hankey, Graeme J., and Flicker, Leon
- Published
- 2024
- Full Text
- View/download PDF
10. Testosterone and the risk of incident atrial fibrillation in older men: further analysis of the ASPREE study
- Author
-
Tran, Cammie, Yeap, Bu B., Ball, Jocasta, Clayton-Chubb, Daniel, Hussain, Sultana Monira, Brodtmann, Amy, Tonkin, Andrew M., Neumann, Johannes T., Schneider, Hans G., Fitzgerald, Sharyn, Woods, Robyn L., and McNeil, John J.
- Published
- 2024
- Full Text
- View/download PDF
11. Testosterone and Cardiovascular Effects
- Author
-
Yeap, Bu B. and Hohl, Alexandre, editor
- Published
- 2023
- Full Text
- View/download PDF
12. Group-based behaviour therapy improves self-care, glycaemic control and distress in adults with type 1 diabetes
- Author
-
Burkhardt, Melanie S., Pirri, Carlo, Summers, Mark A., Barrie, Pixie, Aghabozorgi, Mahnaz, Fegan, P. Gerry, and Yeap, Bu B.
- Published
- 2024
- Full Text
- View/download PDF
13. Association of serum vitamin D with diagnosis and growth of abdominal aortic aneurysm
- Author
-
Thanigaimani, Shivshankar, Neale, Rachel E., Waterhouse, Mary, Moxon, Joseph V., Yeap, Bu B., Norman, Paul E., Flicker, Leon, Hankey, Graeme J., Jenkins, Jason, Quigley, Frank, Clarke, Michael W., and Golledge, Jonathan
- Published
- 2024
- Full Text
- View/download PDF
14. Association of serum vitamin D with diagnosis and growth of abdominal aortic aneurysm
- Author
-
Shivshankar Thanigaimani, PhD, Rachel E. Neale, PhD, Mary Waterhouse, PhD, Joseph V. Moxon, PhD, Bu B. Yeap, PhD, Paul E. Norman, PhD, Leon Flicker, PhD, Graeme J. Hankey, PhD, Jason Jenkins, PhD, Frank Quigley, PhD, Michael W. Clarke, PhD, and Jonathan Golledge, MA, FRCS, FRACS
- Subjects
Vitamin D ,Abdominal aortic aneurysm ,AAA diagnosis ,AAA growth ,Diseases of the circulatory (Cardiovascular) system ,RC666-701 - Abstract
Objective: We examined the associations between 25-hydroxy vitamin D (25(OH)D3) concentration and the diagnosis and growth of abdominal aortic aneurysm (AAA). Methods: AAA cases and healthy controls were recruited from vascular centers or the community. A subset of participants with AAA were monitored by repeat ultrasound examination to assess AAA growth. Serum 25(OH)D3 concentration was measured using a validated mass spectrometry method and categorized into guideline-recommended cut-points after deseasonalization. The associations between deseasonalized 25(OH)D3 concentration and AAA diagnosis and growth were examined using logistic regression and linear mixed effects modeling. Results: A total of 4673 participants consisting of 873 (455 controls and 418 cases) from Queensland and 3800 (3588 controls and 212 cases) from Western Australia were recruited. For every 1 standard deviation increase in 25(OH)D3 concentration, odds of AAA diagnosis was significantly reduced in both Queensland (adjusted odds ratio: 0.81; 95% confidence interval [CI]: 0.69-0.95; P = .009) and Western Australia (adjusted odds ratio: 0.80; 95% CI: 0.68-0.94; P = .005) cohorts. A subset of 310 eligible participants with small AAA from both regions were followed for a median of 4.2 (interquartile range: 2.0-5.8) years. Compared with vitamin D sufficient participants (50 to ˂75 nmol/L), annual mean AAA growth was significantly greater in those with higher vitamin D (≥75 nmol/L) (adjusted mean difference: 0.1 mm/y, 95% CI: 0.1-0.2; P < .001). Conclusions: High 25(OH)D3 concentration was paradoxically associated with a lower likelihood of AAA diagnosis and faster AAA growth. Further research is needed to resolve these conflicting findings. : Clinical Relevance: The findings of this study suggest that relative vitamin D deficiency increases the risk of abdominal aortic aneurysm diagnosis, but paradoxically high circulating markers of vitamin D are associated with faster aneurysm growth. These findings support the need for vitamin D sufficiency not excess, but need validation in other cohorts before incorporation into clinical management protocols.
- Published
- 2024
- Full Text
- View/download PDF
15. The optimal healthy ranges of thyroid function defined by the risk of cardiovascular disease and mortality: systematic review and individual participant data meta-analysis
- Author
-
Xu, Yanning, Derakhshan, Arash, Hysaj, Ola, Wildisen, Lea, Ittermann, Till, Pingitore, Alessandro, Abolhassani, Nazanin, Medici, Marco, Kiemeney, Lambertus A L M, Riksen, Niels P, Dullaart, Robin P F, Trompet, Stella, Dörr, Marcus, Brown, Suzanne J, Schmidt, Börge, Führer-Sakel, Dagmar, Vanderpump, Mark P J, Muendlein, Axel, Drexel, Heinz, Fink, Howard A, Ikram, M Kamran, Kavousi, Maryam, Rhee, Connie M, Bensenor, Isabela M, Azizi, Fereidoun, Hankey, Graeme J, Iacoviello, Massimo, Imaizumi, Misa, Ceresini, Graziano, Ferrucci, Luigi, Sgarbi, José A, Bauer, Douglas C, Wareham, Nick, Boelaert, Kristien, Bakker, Stephan J L, Jukema, J Wouter, Vaes, Bert, Iervasi, Giorgio, Yeap, Bu B, Westendorp, Rudi G J, Korevaar, Tim I M, Völzke, Henry, Razvi, Salman, Gussekloo, Jacobijn, Walsh, John P, Cappola, Anne R, Rodondi, Nicolas, Peeters, Robin P, and Chaker, Layal
- Published
- 2023
- Full Text
- View/download PDF
16. Balance and Strength Measures are Associated With Mortality in Older Men
- Author
-
Paterson, Jack, Trevenen, Michelle, Hill, Keith, Almeida, Osvaldo P., Yeap, Bu B., Golledge, Jonathan, Hankey, Graeme J., and Flicker, Leon
- Published
- 2023
- Full Text
- View/download PDF
17. Associations of Diabetes and Hyperglycaemia with Extent and Outcomes of Acute Burn Injuries
- Author
-
Jeffrey Chandra, Edward Raby, Fiona M. Wood, P. Gerry Fegan, and Bu B. Yeap
- Subjects
diabetes ,stress hyperglycaemia ,burns ,hospitalisation ,Biology (General) ,QH301-705.5 - Abstract
Background: Severe burns may induce hyperglycaemia in the absence of diabetes, but how glucose trajectories relate to burns outcomes is unclear. Aim: To assess incidence of hyperglycaemia following acute burn injury, and associations with diabetes history and length of stay (LOS). Methods: Retrospective cohort study of adults admitted with acute burns to tertiary centres. Blood glucose level (BGL), hyperglycaemic episodes (BGL ≥ 11.1 mmol/L) and hyperglycaemic days were recorded. Stress hyperglycaemia was defined as BGL ≥ 11.1 mmol/L without a diabetes history. Results: A total of 30 participants had a diabetes history and 260 did not. Participants with known diabetes had higher mean BGLs (9.7 vs. 9.0 mmol/L, p < 0.001), more hyperglycaemic episodes (28.0 vs. 17.2%, p < 0.001) and hyperglycaemic days (51 vs. 21%, p < 0.001), compared to those without diabetes, despite smaller burns (total body surface area 1.0 vs. 14.8%, p < 0.001). Fourteen participants with stress hyperglycaemia had similar BGLs (at admission 10.3 vs. 11.5 mmol/L; during inpatient stay 9.9 vs. 9.8 mmol/L), more severe burns (15.6% vs. 1.0% TBSA) and longer LOS (18 vs. 7 days, p < 0.001) compared to participants with known diabetes. Extent of burns, having NGT nutrition, age, having inpatient BGL monitoring in the setting of diabetes, or having inpatient BGL monitoring in the absence of diabetes were associated with longer LOS. Conclusions: In participants with known diabetes, small burn injuries were associated with hyperglycaemia. Stress hyperglycaemia can be triggered by major burn injuries, with early and sustained elevation of BGLs. Further research is warranted to improve inpatient management of BGL in patients with acute burn injury.
- Published
- 2024
- Full Text
- View/download PDF
18. Plasma lipoprotein subclass variation in middle-aged and older adults: Sex-stratified distributions and associations with health status and cardiometabolic risk factors
- Author
-
Masuda, Reika, Wist, Julien, Lodge, Samantha, Kimhofer, Torben, Hunter, Michael, Hui, Jennie, Beilby, John P., Burnett, John R., Dwivedi, Girish, Schlaich, Markus P., Bong, Sze-How, Loo, Ruey Leng, Holmes, Elaine, Nicholson, Jeremy K., and Yeap, Bu B.
- Published
- 2023
- Full Text
- View/download PDF
19. Comparison of coronary artery calcium score and cardiovascular risk-stratification by European Society of Cardiology Guidelines and Steno Type 1 Risk Engine in statin-naïve adults with type 1 diabetes
- Author
-
Goh, Yuhan A., Lan, Nick S.R., Linn, Kathryn, Wood, Chris, Gupta, Ashu, Yeap, Bu B., and Fegan, P. Gerry
- Published
- 2023
- Full Text
- View/download PDF
20. An individual participant data analysis of prospective cohort studies on the association between subclinical thyroid dysfunction and depressive symptoms.
- Author
-
Wildisen, Lea, Del Giovane, Cinzia, Moutzouri, Elisavet, Beglinger, Shanthi, Syrogiannouli, Lamprini, Collet, Tinh-Hai, Cappola, Anne R, Åsvold, Bjørn O, Bakker, Stephan JL, Yeap, Bu B, Almeida, Osvaldo P, Ceresini, Graziano, Dullaart, Robin PF, Ferrucci, Luigi, Grabe, Hans, Jukema, J Wouter, Nauck, Matthias, Trompet, Stella, Völzke, Henry, Westendorp, Rudi, Gussekloo, Jacobijn, Klöppel, Stefan, Aujesky, Drahomir, Bauer, Douglas, Peeters, Robin, Feller, Martin, and Rodondi, Nicolas
- Abstract
In subclinical hypothyroidism, the presence of depressive symptoms is often a reason for starting levothyroxine treatment. However, data are conflicting on the association between subclinical thyroid dysfunction and depressive symptoms. We aimed to examine the association between subclinical thyroid dysfunction and depressive symptoms in all prospective cohorts with relevant data available. We performed a systematic review of the literature from Medline, Embase, Cumulative Index to Nursing and Allied Health Literature, and the Cochrane Library from inception to 10th May 2019. We included prospective cohorts with data on thyroid status at baseline and depressive symptoms during follow-up. The primary outcome was depressive symptoms measured at first available follow-up, expressed on the Beck's Depression Inventory (BDI) scale (range 0-63, higher values indicate more depressive symptoms, minimal clinically important difference: 5 points). We performed a two-stage individual participant data (IPD) analysis comparing participants with subclinical hypo- or hyperthyroidism versus euthyroidism, adjusting for depressive symptoms at baseline, age, sex, education, and income (PROSPERO CRD42018091627). Six cohorts met the inclusion criteria, with IPD on 23,038 participants. Their mean age was 60 years, 65% were female, 21,025 were euthyroid, 1342 had subclinical hypothyroidism and 671 subclinical hyperthyroidism. At first available follow-up [mean 8.2 (± 4.3) years], BDI scores did not differ between participants with subclinical hypothyroidism (mean difference = 0.29, 95% confidence interval = - 0.17 to 0.76, I2 = 15.6) or subclinical hyperthyroidism (- 0.10, 95% confidence interval = - 0.67 to 0.48, I2 = 3.2) compared to euthyroidism. This systematic review and IPD analysis of six prospective cohort studies found no clinically relevant association between subclinical thyroid dysfunction at baseline and depressive symptoms during follow-up. The results were robust in all sensitivity and subgroup analyses. Our results are in contrast with the traditional notion that subclinical thyroid dysfunction, and subclinical hypothyroidism in particular, is associated with depressive symptoms. Consequently, our results do not support the practice of prescribing levothyroxine in patients with subclinical hypothyroidism to reduce the risk of developing depressive symptoms.
- Published
- 2020
21. Efficacy and safety of sodium glucose cotransporter 2 inhibitors plus standard care in diabetic kidney disease: A systematic review and meta-analysis
- Author
-
Woodhams, Louise M., Chalmers, Leanne, Sim, Tin Fei, Yeap, Bu B., Schlaich, Markus P., Schultz, Carl, and Hillis, Graham S.
- Published
- 2023
- Full Text
- View/download PDF
22. Testosterone, cognitive decline and dementia in ageing men
- Author
-
Yeap, Bu B. and Flicker, Leon
- Published
- 2022
- Full Text
- View/download PDF
23. The associations of anthropometric, behavioural and sociodemographic factors with circulating concentrations of IGF‐I, IGF‐II, IGFBP‐1, IGFBP‐2 and IGFBP‐3 in a pooled analysis of 16,024 men from 22 studies
- Author
-
Watts, Eleanor L, Perez‐Cornago, Aurora, Appleby, Paul N, Albanes, Demetrius, Ardanaz, Eva, Black, Amanda, Bueno‐de‐Mesquita, H Bas, Chan, June M, Chen, Chu, Chubb, SA Paul, Cook, Michael B, Deschasaux, Mélanie, Donovan, Jenny L, English, Dallas R, Flicker, Leon, Freedman, Neal D, Galan, Pilar, Giles, Graham G, Giovannucci, Edward L, Gunter, Marc J, Habel, Laurel A, Häggström, Christel, Haiman, Christopher, Hamdy, Freddie C, Hercberg, Serge, Holly, Jeff M, Huang, Jiaqi, Huang, Wen‐Yi, Johansson, Mattias, Kaaks, Rudolf, Kubo, Tatsuhiko, Lane, J Athene, Layne, Tracy M, Le Marchand, Loic, Martin, Richard M, Metter, E Jeffrey, Mikami, Kazuya, Milne, Roger L, Morris, Howard A, Mucci, Lorelei A, Neal, David E, Neuhouser, Marian L, Oliver, Steven E, Overvad, Kim, Ozasa, Kotaro, Pala, Valeria, Pernar, Claire H, Pollak, Michael, Rowlands, Mari‐Anne, Schaefer, Catherine A, Schenk, Jeannette M, Stattin, Pär, Tamakoshi, Akiko, Thysell, Elin, Touvier, Mathilde, Trichopoulou, Antonia, Tsilidis, Konstantinos K, Van Den Eeden, Stephen K, Weinstein, Stephanie J, Wilkens, Lynne, Yeap, Bu B, Key, Timothy J, Allen, Naomi E, and Travis, Ruth C
- Subjects
Cancer ,Aging ,Urologic Diseases ,Adult ,Aged ,Aged ,80 and over ,Anthropometry ,Biomarkers ,Tumor ,Cross-Sectional Studies ,Humans ,Insulin-Like Growth Factor Binding Proteins ,Insulin-Like Growth Factor I ,Insulin-Like Growth Factor II ,Male ,Middle Aged ,Neoplasms ,Prospective Studies ,Young Adult ,IGFs ,IGFBPs ,pooled analysis ,correlates ,Oncology and Carcinogenesis ,Oncology & Carcinogenesis - Abstract
Insulin-like growth factors (IGFs) and insulin-like growth factor binding proteins (IGFBPs) have been implicated in the aetiology of several cancers. To better understand whether anthropometric, behavioural and sociodemographic factors may play a role in cancer risk via IGF signalling, we examined the cross-sectional associations of these exposures with circulating concentrations of IGFs (IGF-I and IGF-II) and IGFBPs (IGFBP-1, IGFBP-2 and IGFBP-3). The Endogenous Hormones, Nutritional Biomarkers and Prostate Cancer Collaborative Group dataset includes individual participant data from 16,024 male controls (i.e. without prostate cancer) aged 22-89 years from 22 prospective studies. Geometric means of protein concentrations were estimated using analysis of variance, adjusted for relevant covariates. Older age was associated with higher concentrations of IGFBP-1 and IGFBP-2 and lower concentrations of IGF-I, IGF-II and IGFBP-3. Higher body mass index was associated with lower concentrations of IGFBP-1 and IGFBP-2. Taller height was associated with higher concentrations of IGF-I and IGFBP-3 and lower concentrations of IGFBP-1. Smokers had higher concentrations of IGFBP-1 and IGFBP-2 and lower concentrations of IGFBP-3 than nonsmokers. Higher alcohol consumption was associated with higher concentrations of IGF-II and lower concentrations of IGF-I and IGFBP-2. African Americans had lower concentrations of IGF-II, IGFBP-1, IGFBP-2 and IGFBP-3 and Hispanics had lower IGF-I, IGF-II and IGFBP-3 than non-Hispanic whites. These findings indicate that a range of anthropometric, behavioural and sociodemographic factors are associated with circulating concentrations of IGFs and IGFBPs in men, which will lead to a greater understanding of the mechanisms through which these factors influence cancer risk.
- Published
- 2019
24. A collaborative analysis of individual participant data from 19 prospective studies assesses circulating vitamin D and prostate cancer risk
- Author
-
Travis, Ruth C, Perez-Cornago, Aurora, Appleby, Paul N, Albanes, Demetrius, Joshu, Corinne E, Lutsey, Pamela L, Mondul, Alison M, Platz, Elizabeth A, Weinstein, Stephanie J, Layne, Tracy M, Helzlsouer, Kathy J, Visvanathan, Kala, Palli, Domenico, Peeters, Petra H, Bueno-de-Mesquita, Bas, Trichopoulou, Antonia, Gunter, Marc J, Tsilidis, Konstantinos K, Sánchez, Maria-Jose, Olsen, Anja, Brenner, Hermann, Schöttker, Ben, Perna, Laura, Holleczek, Bernd, Knekt, Paul, Rissanen, Harri, Yeap, Bu B, Flicker, Leon, Almeida, Osvaldo P, Wong, Yuen Yee Elizabeth, Chan, June M, Giovannucci, Edward L, Stampfer, Meir J, Ursin, Giske, Gislefoss, Randi E, Bjørge, Tone, Meyer, Haakon E, Blomhoff, Rune, Tsugane, Shoichiro, Sawada, Norie, English, Dallas R, Eyles, Darryl W, Heath, Alicia K, Williamson, Elizabeth J, Manjer, Jonas, Malm, Johan, Almquist, Martin, Marchand, Loic Le, Haiman, Christopher A, Wilkens, Lynne R, Schenk, Jeannette M, Tangen, Cathy M, Black, Amanda, Cook, Michael B, Huang, Wen-Yi, Ziegler, Regina G, Martin, Richard M, Hamdy, Freddie C, Donovan, Jenny L, Neal, David E, Touvier, Mathilde, Hercberg, Serge, Galan, Pilar, Deschasaux, Mélanie, Key, Timothy J, and Allen, Naomi E
- Subjects
Clinical Trials and Supportive Activities ,Nutrition ,Cancer ,Prostate Cancer ,Urologic Diseases ,Prevention ,Aging ,Clinical Research ,Aged ,Case-Control Studies ,Cross-Sectional Studies ,Humans ,Male ,Middle Aged ,Odds Ratio ,Prospective Studies ,Prostatic Neoplasms ,Risk Assessment ,Risk Factors ,Vitamin D ,Oncology and Carcinogenesis ,Oncology & Carcinogenesis - Abstract
Previous prospective studies assessing the relationship between circulating concentrations of vitamin D and prostate cancer risk have shown inconclusive results, particularly for risk of aggressive disease. In this study, we examine the association between prediagnostic concentrations of 25-hydroxyvitamin D [25(OH)D] and 1,25-dihydroxyvitamin D [1,25(OH)2D] and the risk of prostate cancer overall and by tumor characteristics. Principal investigators of 19 prospective studies provided individual participant data on circulating 25(OH)D and 1,25(OH)2D for up to 13,462 men with incident prostate cancer and 20,261 control participants. ORs for prostate cancer by study-specific fifths of season-standardized vitamin D concentration were estimated using multivariable-adjusted conditional logistic regression. 25(OH)D concentration was positively associated with risk for total prostate cancer (multivariable-adjusted OR comparing highest vs. lowest study-specific fifth was 1.22; 95% confidence interval, 1.13-1.31; P trend < 0.001). However, this association varied by disease aggressiveness (P heterogeneity = 0.014); higher circulating 25(OH)D was associated with a higher risk of nonaggressive disease (OR per 80 percentile increase = 1.24, 1.13-1.36) but not with aggressive disease (defined as stage 4, metastases, or prostate cancer death, 0.95, 0.78-1.15). 1,25(OH)2D concentration was not associated with risk for prostate cancer overall or by tumor characteristics. The absence of an association of vitamin D with aggressive disease does not support the hypothesis that vitamin D deficiency increases prostate cancer risk. Rather, the association of high circulating 25(OH)D concentration with a higher risk of nonaggressive prostate cancer may be influenced by detection bias. SIGNIFICANCE: This international collaboration comprises the largest prospective study on blood vitamin D and prostate cancer risk and shows no association with aggressive disease but some evidence of a higher risk of nonaggressive disease.
- Published
- 2019
25. Characteristics and outcomes of patients with type 1 diabetes admitted with acute coronary syndromes
- Author
-
Nejatian, Marcel M., Lan, Nick S.R., Yeap, Bu B., Dwivedi, Girish, Fegan, P. Gerry, and Ihdayhid, Abdul R.
- Published
- 2022
- Full Text
- View/download PDF
26. Health‐related behaviours and weight status of expectant fathers
- Author
-
Pettigrew, Simone, Jongenelis, Michelle I., Cronin, Sophie, Dana, Liyuwork M., Silva, Desiree, Prescott, Susan L., and Yeap, Bu B.
- Subjects
Fathers -- Health aspects -- Physiological aspects -- Behavior ,Medical research ,Medicine, Experimental ,Health behavior -- Research ,Health - Abstract
: Objective: Little attention has been given to the health status and lifestyle behaviours of expectant fathers. This study aimed to examine health‐related variables in a cohort of expectant fathers to identify potential focus areas for interventions designed to optimise health and wellbeing outcomes in this group. Methods: Partners of pregnant women who accessed antenatal services at a large maternity unit in a Western Australian hospital were recruited as part of the ORIGINS Project. Analyses were conducted on data from 498 expectant fathers who were primarily of mid and high socioeconomic status. Results: Participants reported relatively low levels of smoking and alcohol consumption and higher physical activity compared to national averages. Weight status was consistent with population norms for adult males: 76% were overweight or obese and 62% had a waist girth ≥94cm. Conclusions: Expectant fathers may benefit from health interventions, especially in relation to managing their weight during this phase of their lives and beyond. Implications for public health: Pregnancy represents a valuable opportunity to engage fathers‐to‐be in health interventions. Given identified links between paternal weight status and offspring outcomes, interventions focusing on achieving and maintaining a healthy weight among expectant fathers could be beneficial for families., Parents play a determining role in their children's health and wellbeing from preconception onwards.[sup.1] Influence occurs via a range of pathways including epigenetic, environmental and behavioural mechanisms.[sup.2,3] In terms of [...]
- Published
- 2022
- Full Text
- View/download PDF
27. The Hospital Frailty Risk Score Identifies Fewer Cases of Frailty in a Community-Based Cohort of Older Men Than the FRAIL Scale and Frailty Index
- Author
-
Lopez, Derrick, Murray, Kevin, Preen, David B., Sanfilippo, Frank M., Trevenen, Michelle, Hankey, Graeme J., Yeap, Bu B., Golledge, Jonathan, Almeida, Osvaldo P., and Flicker, Leon
- Published
- 2022
- Full Text
- View/download PDF
28. Tacrolimus Combined with Corticosteroids Improved the Outcome of CIDP Patients with Autoantibodies Against Paranodal Proteins
- Author
-
Yang M, Xu L, Ji S, Gao H, Zhang Q, and Bu B
- Subjects
chronic inflammatory demyelinating polyneuropathy ,paranodal proteins ,tacrolimus ,outcome ,Neurosciences. Biological psychiatry. Neuropsychiatry ,RC321-571 ,Neurology. Diseases of the nervous system ,RC346-429 - Abstract
Meng-ge Yang, Li Xu, Suqiong Ji, Huajie Gao, Qing Zhang, Bitao Bu Department of Neurology, Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology, Wuhan, People’s Republic of ChinaCorrespondence: Bitao Bu, Department of Neurology, Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology, Jiefang Street 1095#, Wuhan, 430000, People’s Republic of China, Email bubitao@tjh.tjmu.edu.cnPurpose: To investigate the response of tacrolimus to chronic inflammatory demyelinating polyneuropathy (CIDP) with autoantibodies against paranodal proteins, including neurofascin-155 (NF155), contactin-1 (CNTN1) and contactin-associated protein 1 (Caspr1).Methods: We retrospectively reviewed all CIDP patients who carried anti-NF155, CNTN1 and Caspr1 antibodies and were treated with tacrolimus at Tongji hospital from Jan 2018 to Apr 2021.Results: There were 58 patients with CIDP and only 9 patients had autoantibodies against paranodal proteins (17.2%). Five of the 9 patients received tacrolimus treatment with an initial dose of 2– 3 mg once daily. One patient with anti-CNTN1 antibody started tacrolimus and corticosteroid treatment, at the first episode and eventually achieved full clinical remission without relapse. Four patients with anti-NF155 or -Caspr1 antibodies experienced relapse during corticosteroids tapering. Then, they were given oral tacrolimus and presented with clinical improvement. During follow-up, only one patient developed worsening weakness due to unreasonable tacrolimus discontinuation. Moreover, 3 patients were successfully withdrawn from corticosteroids and 2 patients took corticosteroids at low maintenance dose (10mg/d) after tacrolimus treatment. No severe adverse events were observed in all the patients.Conclusion: Patients with autoantibodies against paranodal proteins had a better long-term outcome after adding tacrolimus. Combination therapy with corticosteroids and tacrolimus may be an effective therapeutic regimen.Keywords: chronic inflammatory demyelinating polyneuropathy, paranodal proteins, tacrolimus, outcome
- Published
- 2022
29. Health‐related behaviours and weight status of expectant fathers
- Author
-
Simone Pettigrew, Michelle I. Jongenelis, Sophie Cronin, Liyuwork M. Dana, Desiree Silva, Susan L. Prescott, and Bu B. Yeap
- Subjects
ORIGINS Project ,antenatal ,fathers ,paternal ,pregnancy ,Public aspects of medicine ,RA1-1270 - Abstract
Abstract Objective: Little attention has been given to the health status and lifestyle behaviours of expectant fathers. This study aimed to examine health‐related variables in a cohort of expectant fathers to identify potential focus areas for interventions designed to optimise health and wellbeing outcomes in this group. Methods: Partners of pregnant women who accessed antenatal services at a large maternity unit in a Western Australian hospital were recruited as part of the ORIGINS Project. Analyses were conducted on data from 498 expectant fathers who were primarily of mid and high socioeconomic status. Results: Participants reported relatively low levels of smoking and alcohol consumption and higher physical activity compared to national averages. Weight status was consistent with population norms for adult males: 76% were overweight or obese and 62% had a waist girth ≥94cm. Conclusions: Expectant fathers may benefit from health interventions, especially in relation to managing their weight during this phase of their lives and beyond. Implications for public health: Pregnancy represents a valuable opportunity to engage fathers‐to‐be in health interventions. Given identified links between paternal weight status and offspring outcomes, interventions focusing on achieving and maintaining a healthy weight among expectant fathers could be beneficial for families.
- Published
- 2022
- Full Text
- View/download PDF
30. Is incident cancer in later life associated with lower incidence of dementia?
- Author
-
Almeida, Osvaldo P., Hankey, Graeme J., Yeap, Bu B., Golledge, Jonathan, Etherton-Beer, Christopher, Robinson, Suzanne, and Flicker, Leon
- Abstract
Cancer has been associated with lower risk of dementia, although methodological issues raise concerns about the validity of this association. We recruited 31,080 men aged 65–85 years who were free of cancer and dementia, and followed them for up to 22 years. We used health record linkage to identify incident cases of cancer and dementia, and split time span to investigate this association. 18,693 (60.1%) and 6897 (22.2%) participants developed cancer and dementia during follow-up. The hazard ratio (HR) of dementia associated with cancer was 1.13 (95% CI = 1.07, 1.20) and dropped to 0.85 (95% CI = 0.80, 0.91) when 449 participants who developed dementia within 2 years were excluded. The diagnosis of cancer seems to facilitate the early detection of dementia cases. Older participants who survive cancer for 2 or more years have lower risk of receiving the diagnosis of dementia over time. The factors that mediate this association remain unclear. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
31. Association of Serum Phosphate, Calcium and Alkaline Phosphatase With Risk of Incident Fractures in Healthy Older Adults.
- Author
-
Hussain, Sultana Monira, Seeman, Ego, Schneider, Hans G, Ebeling, Peter R, Barker, Anna L, Polkinghorne, Kevan, Newman, Anne B, Yu, Chenglong, Lacaze, Paul, Owen, Alice, Tran, Cammie, Nelson, Mark R, Woods, Robyn Lorraine, Yeap, Bu B, Clark, David, Beilin, Lawrence J, and McNeil, John J
- Subjects
OLDER people ,OLDER men ,ALKALINE phosphatase ,CUBIC curves ,BONE resorption ,ASPIRIN ,FRACTURE healing - Abstract
Context Aging increases fracture risk through bone loss and microarchitecture deterioration due to an age-related imbalance in bone resorption and formation during bone remodeling. Objective We examined the associations between levels of phosphate, calcium (Ca), and alkaline phosphatase (ALP), and fracture risk in initially healthy older individuals. Methods A post hoc analysis of the Aspirin in Reducing Events in the Elderly (ASPREE) trial recruited 16 703 Australian participants aged 70 years and older and 2411 US participants aged 65 years and older. Analyses were conducted on ASPREE-Fracture substudy participants from Australia with serum calcium, phosphate, and ALP measurement. Fracture data were collected post randomization. Cox regression was used to calculate hazard ratios (HRs) and 95% CIs. Phosphate, Ca, and ALP were analyzed in deciles (D1-D10), with deciles 4 to 7 (31%-70%) as the reference category. Restricted cubic spline curves were used to identify nonlinear associations. Results Of the 9915 participants, 907 (9.2%) individuals had incident fractures recorded over 3.9 (SD 1.4) years. In the fully adjusted model, men in the top decile (D10) of phosphate had a 78% higher risk of incident fracture (HR 1.78; 95% CI, 1.25-2.54). No such association was observed for women (HR 1.09; 95% CI, 0.83-1.44). The population attributable fraction in men within the D10 phosphate category is 6.9%. Conclusion This result confirms that high-normal serum phosphate levels are associated with increased fracture risk in older men. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
32. Incretin-Based Weight Loss Pharmacotherapy: Can Resistance Exercise Optimize Changes in Body Composition?
- Author
-
Locatelli, João Carlos, Costa, Juliene Gonçalves, Haynes, Andrew, Naylor, Louise H., Fegan, P. Gerry, Yeap, Bu B., and Green, Daniel J.
- Subjects
BODY composition ,GLUCAGON-like peptide 1 ,WEIGHT loss ,LEAN body mass ,MUSCLE mass - Abstract
This narrative review highlights the degree to which new antiobesity medications based on gut-derived nutrient-stimulated hormones (incretins) cause loss of lean mass, and the importance of resistance exercise to preserve muscle. Glucagon-like peptide 1 receptor agonists (GLP-1RA) induce substantial weight loss in randomized trials, effects that may be enhanced in combination with glucose-dependent insulinotropic polypeptide (GIP) receptor agonists. Liraglutide and semaglutide (GLP-1RA), tirzepatide (GLP-1 and GIP receptor dual agonist), and retatrutide (GLP-1, GIP, and glucagon receptor triple agonist) are peptides with incretin agonist activity that induce ∼15–24% weight loss in adults with overweight and obesity, alongside beneficial impacts on blood pressure, cholesterol, blood glucose, and insulin. However, these agents also cause rapid and significant loss of lean mass (∼10% or ∼6 kg), comparable to a decade or more of aging. Maintaining muscle mass and function as humans age is crucial to avoiding sarcopenia and frailty, which are strongly linked to morbidity and mortality. Studies indicate that supervised resistance exercise training interventions with a duration >10 weeks can elicit large increases in lean mass (∼3 kg) and strength (∼25%) in men and women. After a low-calorie diet, combining aerobic exercise with liraglutide improved weight loss maintenance compared with either alone. Retaining lean mass during incretin therapy could blunt body weight (and fat) regain on cessation of weight loss pharmacotherapy. We propose that tailored resistance exercise training be recommended as an adjunct to incretin therapy to optimize changes in body composition by preserving lean mass while achieving fat loss. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
33. Testosterone treatment combined with exercise to improve muscle strength, physical function and quality of life in men affected by inclusion body myositis: A randomised, double-blind, placebo-controlled, crossover trial
- Author
-
Sophia G. Connor, Timothy J. Fairchild, Yvonne C. Learmonth, Kelly Beer, Ian Cooper, Glenn Boardman, Shaun Y. M. Teo, Behnaz Shatahmasseb, Rui Zhang, Krystyne Hiscock, Jerome D. Coudert, Bu B. Yeap, and Merrilee Needham
- Subjects
Medicine ,Science - Abstract
Introduction Inclusion body myositis (IBM) is the most commonly acquired skeletal muscle disease of older adults involving both autoimmune attack and muscle degeneration. As exercise training can improve outcomes in IBM, this study assessed whether a combination of testosterone supplementation and exercise training would improve muscle strength, physical function and quality of life in men affected by IBM, more than exercise alone. Methods This pilot study was a single site randomised, double-blind, placebo-controlled, crossover study. Testosterone (exercise and testosterone cream) and placebo (exercise and placebo cream) were each delivered for 12 weeks, with a two-week wash-out between the two periods. The primary outcome measure was improvement in quadriceps isokinetic muscle strength. Secondary outcomes included assessment of isokinetic peak flexion force, walk capacity and patient reported outcomes, and other tests, comparing results between the placebo and testosterone arms. A 12-month Open Label Extension (OLE) was offered using the same outcome measures collected at 6 and 12-months. Results 14 men completed the trial. There were no significant improvements in quadriceps extension strength or lean body mass, nor any of the secondary outcomes. Improvement in the RAND Short Form 36 patient reported outcome questionnaire ‘emotional wellbeing’ sub-category was reported during the testosterone arm compared to the placebo arm (mean difference [95% CI]: 6.0 points, [95% CI 1.7,10.3]). The OLE demonstrated relative disease stability over the 12-month period but with a higher number of testosterone-related adverse events. Conclusions Adding testosterone supplementation to exercise training did not significantly improve muscle strength or physical function over a 12-week intervention period, compared to exercise alone. However, the combination improved emotional well-being over this period, and relative stabilisation of disease was found during the 12-month OLE. A longer duration trial involving a larger group of participants is warranted.
- Published
- 2023
34. Low Free Testosterone and Prostate Cancer Risk: A Collaborative Analysis of 20 Prospective Studies
- Author
-
Watts, Eleanor L, Appleby, Paul N, Perez-Cornago, Aurora, Bueno-de-Mesquita, H Bas, Chan, June M, Chen, Chu, Cohn, Barbara A, Cook, Michael B, Flicker, Leon, Freedman, Neal D, Giles, Graham G, Giovannucci, Edward, Gislefoss, Randi E, Hankey, Graeme J, Kaaks, Rudolf, Knekt, Paul, Kolonel, Laurence N, Kubo, Tatsuhiko, Le Marchand, Loïc, Luben, Robert N, Luostarinen, Tapio, Männistö, Satu, Metter, E Jeffrey, Mikami, Kazuya, Milne, Roger L, Ozasa, Kotaro, Platz, Elizabeth A, Quirós, J Ramón, Rissanen, Harri, Sawada, Norie, Stampfer, Meir, Stanczyk, Frank Z, Stattin, Pär, Tamakoshi, Akiko, Tangen, Catherine M, Thompson, Ian M, Tsilidis, Konstantinos K, Tsugane, Shoichiro, Ursin, Giske, Vatten, Lars, Weiss, Noel S, Yeap, Bu B, Allen, Naomi E, Key, Timothy J, and Travis, Ruth C
- Subjects
Cancer ,Clinical Research ,Prevention ,Urologic Diseases ,Prostate Cancer ,Aging ,Aetiology ,2.1 Biological and endogenous factors ,Adult ,Aged ,Biomarkers ,Case-Control Studies ,Down-Regulation ,Humans ,Male ,Middle Aged ,Neoplasm Grading ,Prospective Studies ,Prostatic Neoplasms ,Protective Factors ,Risk Assessment ,Risk Factors ,Testosterone ,Time Factors ,Androgens Pooled analysis ,Prospective studies ,Prostate cancer ,Sex hormones ,Epidemiology ,Androgens ,Pooled analysis ,Clinical Sciences ,Urology & Nephrology - Abstract
BackgroundExperimental and clinical evidence implicates testosterone in the aetiology of prostate cancer. Variation across the normal range of circulating free testosterone concentrations may not lead to changes in prostate biology, unless circulating concentrations are low. This may also apply to prostate cancer risk, but this has not been investigated in an epidemiological setting.ObjectiveTo examine whether men with low concentrations of circulating free testosterone have a reduced risk of prostate cancer.Design, setting, and participantsAnalysis of individual participant data from 20 prospective studies including 6933 prostate cancer cases, diagnosed on average 6.8 yr after blood collection, and 12 088 controls in the Endogenous Hormones, Nutritional Biomarkers and Prostate Cancer Collaborative Group.Outcome measurements and statistical analysisOdds ratios (ORs) of incident overall prostate cancer and subtypes by stage and grade, using conditional logistic regression, based on study-specific tenths of calculated free testosterone concentration.Results and limitationsMen in the lowest tenth of free testosterone concentration had a lower risk of overall prostate cancer (OR=0.77, 95% confidence interval [CI] 0.69-0.86; p
- Published
- 2018
35. Reduction in femoral neck and total hip bone mineral density following hospitalisation for diabetes-related foot ulceration
- Author
-
Marcel M. Nejatian, Salar Sobhi, Blake N. Sanchez, Kathryn Linn, Laurens Manning, Shuen-Chyn Soh, Jonathan Hiew, J. Carsten Ritter, Bu B. Yeap, and Emma J. Hamilton
- Subjects
Medicine ,Science - Abstract
Abstract Management of diabetes-related foot ulceration (DFU) includes pressure offloading resulting in a period of reduced activity. The metabolic effects of this are unknown. This study aims to investigate changes in bone mineral density (BMD) and body composition 12 weeks after hospitalisation for DFU. A longitudinal, prospective, observational study of 22 people hospitalised for DFU was conducted. Total body, lumbar spine, hip and forearm BMD, and total lean and fat mass were measured by dual-energy X-ray absorptiometry (DXA) during and 12 weeks after hospitalisation for DFU. Significant losses in total hip BMD of the ipsilateral limb (− 1.7%, p
- Published
- 2021
- Full Text
- View/download PDF
36. Lipoprotein(a) in Patients With Type 2 Diabetes and Premature Coronary Artery Disease in the Coronary Care Unit
- Author
-
Lan, Nick S.R., Chan, Dick C., Pang, Jing, Fegan, P. Gerry, Yeap, Bu B., Rankin, James M., Schultz, Carl J., Watts, Gerald F., and Bell, Damon A.
- Published
- 2021
- Full Text
- View/download PDF
37. Testosterone treatment to prevent or revert type 2 diabetes in men enrolled in a lifestyle programme (T4DM): a randomised, double-blind, placebo-controlled, 2-year, phase 3b trial
- Author
-
Wittert, Gary, Bracken, Karen, Robledo, Kristy P, Grossmann, Mathis, Yeap, Bu B, Handelsman, David J, Stuckey, Bronwyn, Conway, Ann, Inder, Warrick, McLachlan, Robert, Allan, Carolyn, Jesudason, David, Fui, Mark Ng Tang, Hague, Wendy, Jenkins, Alicia, Daniel, Mark, Gebski, Val, and Keech, Anthony
- Published
- 2021
- Full Text
- View/download PDF
38. Gut Microbiome and Associated Metabolites Following Bariatric Surgery and Comparison to Healthy Controls
- Author
-
Adilah F. Ahmad, Jose A. Caparrós-Martín, Silvia Lee, Fergal O’Gara, Bu B. Yeap, Daniel J. Green, Mohammed Ballal, Natalie C. Ward, and Girish Dwivedi
- Subjects
obesity ,bariatric surgery ,cardiovascular disease ,dysbiosis ,gut microbiome ,short chain fatty acids ,Biology (General) ,QH301-705.5 - Abstract
The gut microbiome plays a significant role in regulating the host’s ability to store fat, which impacts the development of obesity. This observational cohort study recruited obese adult men and women scheduled to undergo sleeve gastrectomy and followed up with them 6 months post-surgery to analyse their microbial taxonomic profiles and associated metabolites in comparison to a healthy control group. There were no significant differences in the gut bacterial diversity between the bariatric patients at baseline and at follow-up or between the bariatric patients and the cohort of healthy controls. However, there were differential abundances in specific bacterial groups between the two cohorts. The bariatric patients were observed to have significant enrichment in Granulicatella at baseline and Streptococcus and Actinomyces at follow-up compared to the healthy controls. Several operational taxonomic units assigned to commensal Clostridia were significantly reduced in the stool of bariatric patients both at baseline and follow-up. When compared to a healthy cohort, the plasma levels of the short chain fatty acid acetate were significantly higher in the bariatric surgery group at baseline. This remained significant when adjusted for age and sex (p = 0.013). The levels of soluble CD14 and CD163 were significantly higher (p = 0.0432 and p = 0.0067, respectively) in the bariatric surgery patients compared to the healthy controls at baseline. The present study demonstrated that there are alterations in the abundance of certain bacterial groups in the gut microbiome of obese patients prior to bariatric surgery compared to healthy individuals, which persist post-sleeve gastrectomy.
- Published
- 2023
- Full Text
- View/download PDF
39. Testosterone Treatment, Weight Loss, and Health-related Quality of Life and Psychosocial Function in Men: A 2-year Randomized Controlled Trial.
- Author
-
Grossmann, Mathis, Robledo, Kristy P, Daniel, Mark, Handelsman, David J, Inder, Warrick J, Stuckey, Bronwyn G A, Yeap, Bu B, Fui, Mark Ng Tang, Bracken, Karen, Allan, Carolyn A, Jesudason, David, Zajac, Jeffrey D, and Wittert, Gary A
- Subjects
PSYCHOSOCIAL functioning ,QUALITY of life ,WEIGHT loss ,RANDOMIZED controlled trials ,TESTOSTERONE ,MEN'S health ,IMPOTENCE ,PATHOLOGIC neovascularization - Abstract
Objective To determine the effect of testosterone vs placebo treatment on health-related quality of life (HR-QOL) and psychosocial function in men without pathologic hypogonadism in the context of a lifestyle intervention. Design, Setting, Participants Secondary analysis of a 2-year randomized controlled testosterone therapy trial for prevention or reversal of newly diagnosed type 2 diabetes, enrolling men ≥ 50 years at high risk for type 2 diabetes from 6 Australian centers. Interventions Injectable testosterone undecanoate or matching placebo on the background of a community-based lifestyle program. Main Outcomes Self-reported measures of HR-QOL/psychosocial function. Results Of 1007 participants randomized into the Testosterone for Type 2 Diabetes Mellitus (T4DM) trial, 648 (64%) had complete data available for all HR-QOL/psychosocial function assessments at baseline and 2 years. Over 24 months, while most measures were not different between treatment arms, testosterone treatment, compared with placebo, improved subjective social status and sense of coherence. Baseline HR-QOL/psychosocial function measures did not predict the effect of testosterone treatment on glycemic outcomes, primary endpoints of T4DM. Irrespective of treatment allocation, larger decreases in body weight were associated with improved mental quality of life, mastery, and subjective social status. Men with better baseline physical function, greater sense of coherence, and fewer depressive symptoms experienced greater associated decreases in body weight, with similar effects on waist circumference. Conclusion In this diabetes prevention trial, weight loss induced by a lifestyle intervention improved HR-QOL and psychosocial function in more domains than testosterone treatment. The magnitude of weight and waist circumference reduction were predicted by baseline physical function, depressive symptomology, and sense of coherence. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
40. Testosterone therapy in older men: clinical implications of recent landmark trials.
- Author
-
Grossmann, Mathis, Anawalt, Bradley D, and Yeap, Bu B
- Abstract
Testosterone therapy for men with hypogonadism due to identifiable hypothalamic-pituitary-testicular (HPT) pathology is uncontroversial. However, the risks and benefits of testosterone for men with clinical features of hypogonadism in the absence of identifiable HPT axis pathology have been uncertain. Recent landmark placebo-controlled trials assessed the benefits and risks of testosterone therapy (≤3 years) for middle-aged and older men with symptoms and possible signs of hypogonadism or end-organ androgen deficiency, low or low-normal serum testosterone concentrations, but no HPT pathology: Testosterone therapy (1) had modest—but clinically significant—benefits on average self-reported energy and mood, sexual function, and satisfaction; (2) in conjunction with a lifestyle programme, reversed or reduced incident type 2 diabetes mellitus (T2D) in men at high risk of or newly diagnosed with T2D; (3) modestly improved objectively assessed muscle strength and timed walking distance; (4) increased bone density and strength, but did not reduce falls or typical osteoporotic fractures and surprisingly increased the risk of fractures typically attributable to trauma; and (5) did not significantly increase the risk of myocardial infarction, stroke, or prostate cancer. These landmark trials help to inform clinical decision-making about testosterone therapy for men. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
41. Short-term outcomes following coronary artery bypass graft surgery in insulin treated and non-insulin treated diabetes: A tertiary hospital experience in Australia
- Author
-
Lan, Nick S.R., Ali, Umar, Fegan, P. Gerry, Larbalestier, Robert, Hitchen, Sarah A., Hort, Adam, and Yeap, Bu B.
- Published
- 2020
- Full Text
- View/download PDF
42. Osteocalcin and its forms across the lifespan in adult men
- Author
-
Smith, Cassandra, Voisin, Sarah, Al Saedi, Ahmed, Phu, Steven, Brennan-Speranza, Tara, Parker, Lewan, Eynon, Nir, Hiam, Danielle, Yan, Xu, Scott, David, Blekkenhorst, Lauren C., Lewis, Joshua R., Seeman, Ego, Byrnes, Elizabeth, Flicker, Leon, Duque, Gustavo, Yeap, Bu B., and Levinger, Itamar
- Published
- 2020
- Full Text
- View/download PDF
43. Testosterone and the Risk of Incident Atrial Fibrillation in Older Men: Further Analysis of the ASPREE Study
- Author
-
Tran, Cammie, primary, Yeap, Bu B., additional, Ball, Jocasta, additional, Clayton-Chubb, Daniel, additional, Hussain, Sultana Monira, additional, Brodtmann, Amy, additional, Tonkin, Andrew M., additional, Neumann, Johannes T., additional, Schneider, Hans G., additional, Fitzgerald, Sharyn, additional, Woods, Robyn, additional, and McNeil, John J., additional
- Published
- 2024
- Full Text
- View/download PDF
44. Empagliflozin and left ventricular diastolic function following an acute coronary syndrome in patients with type 2 diabetes
- Author
-
Lan, Nick S. R., Yeap, Bu B., Fegan, P. Gerry, Green, Gillian, Rankin, James M., and Dwivedi, Girish
- Published
- 2021
- Full Text
- View/download PDF
45. Hypothalamo–Pituitary–Testicular Axis Function in Systemic Diseases and Effects of Medications
- Author
-
Wittert, Gary, additional, Yeap, Bu B., additional, and Grossmann, Mathis, additional
- Published
- 2021
- Full Text
- View/download PDF
46. Immunoregulatory effects of testosterone supplementation combined with exercise training in men with Inclusion Body Myositis: a double‐blind, placebo‐controlled, cross‐over trial
- Author
-
Jerome D Coudert, Nataliya Slater, Anuradha Sooda, Kelly Beer, Ee Mun Lim, Conchita Boyder, Rui Zhang, Frank L Mastaglia, Yvonne C Learmonth, Timothy J Fairchild, Bu B Yeap, and Merrilee Needham
- Subjects
autoimmunity ,clinical trial ,exercise therapy ,Inclusion Body Myositis ,testosterone ,Immunologic diseases. Allergy ,RC581-607 - Abstract
Abstract Objectives Sporadic Inclusion Body Myositis (IBM) is an inflammatory muscle disease affecting individuals over the age of 45, leading to progressive muscle wasting, disability and loss of independence. Histologically, IBM is characterised by immune changes including myofibres expressing major histocompatibility complex molecules and invaded by CD8+ T cells and macrophages, and by degenerative changes including protein aggregates organised in inclusion bodies, rimmed vacuoles and mitochondrial abnormalities. There is currently no cure, and regular exercise is currently the only recognised treatment effective at limiting muscle weakening, atrophy and loss of function. Testosterone exerts anti‐inflammatory effects, inhibiting effector T‐cell differentiation and pro‐inflammatory cytokine production. Methods We conducted a double‐blind, placebo‐controlled, cross‐over trial in men with IBM, to assess whether a personalised progressive exercise training combined with application of testosterone, reduced the inflammatory immune response associated with this disease over and above exercise alone. To assess intervention efficacy, we immunophenotyped blood immune cells by flow cytometry, and measured serum cytokines and chemokines by Luminex immunoassay. Results Testosterone supplementation resulted in modest yet significant count reduction in the classical monocyte subset as well as eosinophils. Testosterone‐independent immunoregulatory effects attributed to exercise included altered proportions of some monocyte, T‐ and B‐cell subsets, and reduced IL‐12, IL‐17, TNF‐α, MIP‐1β and sICAM‐1 in spite of interindividual variability. Conclusion Overall, our findings indicate anti‐inflammatory effects of exercise training in IBM patients, whilst concomitant testosterone supplementation provides some additional changes. Further studies combining testosterone and exercise would be worthwhile in larger cohorts and longer testosterone administration periods.
- Published
- 2022
- Full Text
- View/download PDF
47. Reduction in femoral neck and total hip bone mineral density following hospitalisation for diabetes-related foot ulceration
- Author
-
Nejatian, Marcel M., Sobhi, Salar, Sanchez, Blake N., Linn, Kathryn, Manning, Laurens, Soh, Shuen-Chyn, Hiew, Jonathan, Ritter, J. Carsten, Yeap, Bu B., and Hamilton, Emma J.
- Published
- 2021
- Full Text
- View/download PDF
48. Telephone call reminders did not increase screening uptake more than SMS reminders: a recruitment study within a trial
- Author
-
Bracken, Karen, Keech, Anthony, Hague, Wendy, Kirby, Adrienne, Robledo, Kristy P., Allan, Carolyn, Conway, Ann, Daniel, Mark, Gebski, Val, Grossmann, Mathis, Handelsman, David J., Inder, Warrick, Jenkins, Alicia, McLachlan, Robert, Stuckey, Bronwyn, Yeap, Bu B., and Wittert, Gary
- Published
- 2019
- Full Text
- View/download PDF
49. Associations of Testosterone and Related Hormones With All-Cause and Cardiovascular Mortality and Incident Cardiovascular Disease in Men: Individual Participant Data Meta-analyses.
- Author
-
Yeap, Bu B., Marriott, Ross J., Dwivedi, Girish, Adams, Robert J., Antonio, Leen, Ballantyne, Christie M., Bauer, Douglas C., Bhasin, Shalender, Biggs, Mary L., Cawthon, Peggy M., Couper, David J., Dobs, Adrian S., Flicker, Leon, Handelsman, David J., Hankey, Graeme J., Hannemann, Anke, Haring, Robin, Hsu, Benjumin, Martin, Sean A., and Matsumoto, Alvin M.
- Subjects
- *
MORTALITY , *CARDIOVASCULAR diseases , *HDL cholesterol , *SEX hormones , *OLDER men ,CARDIOVASCULAR disease related mortality - Abstract
The relationship between testosterone and related hormones and cardiovascular and mortality outcomes is debated. The authors of this study obtained individual patient–level data from 9 cohort studies and aggregate data from 11 studies in total. These data enabled them to describe the associations of testosterone, sex hormone–binding globulin (SHBG), luteinizing hormone (LH), dihydrotestosterone (DHT), and estradiol with all-cause mortality, cardiovascular death, and incident cardiovascular events while accounting for other cardiac risk factors. Background: Whether circulating sex hormones modulate mortality and cardiovascular disease (CVD) risk in aging men is controversial. Purpose: To clarify associations of sex hormones with these outcomes. Data Sources: Systematic literature review to July 2019, with bridge searches to March 2024. Study Selection: Prospective cohort studies of community-dwelling men with sex steroids measured using mass spectrometry and at least 5 years of follow-up. Data Extraction: Independent variables were testosterone, sex hormone–binding globulin (SHBG), luteinizing hormone (LH), dihydrotestosterone (DHT), and estradiol concentrations. Primary outcomes were all-cause mortality, CVD death, and incident CVD events. Covariates included age, body mass index, marital status, alcohol consumption, smoking, physical activity, hypertension, diabetes, creatinine concentration, ratio of total to high-density lipoprotein cholesterol, and lipid medication use. Data Synthesis: Nine studies provided individual participant data (IPD) (255 830 participant-years). Eleven studies provided summary estimates (n = 24 109). Two-stage random-effects IPD meta-analyses found that men with baseline testosterone concentrations below 7.4 nmol/L (<213 ng/dL), LH concentrations above 10 IU/L, or estradiol concentrations below 5.1 pmol/L had higher all-cause mortality, and those with testosterone concentrations below 5.3 nmol/L (<153 ng/dL) had higher CVD mortality risk. Lower SHBG concentration was associated with lower all-cause mortality (median for quintile 1 [Q1] vs. Q5, 20.6 vs. 68.3 nmol/L; adjusted hazard ratio [HR], 0.85 [95% CI, 0.77 to 0.95]) and lower CVD mortality (adjusted HR, 0.81 [CI, 0.65 to 1.00]). Men with lower baseline DHT concentrations had higher risk for all-cause mortality (median for Q1 vs. Q5, 0.69 vs. 2.45 nmol/L; adjusted HR, 1.19 [CI, 1.08 to 1.30]) and CVD mortality (adjusted HR, 1.29 [CI, 1.03 to 1.61]), and risk also increased with DHT concentrations above 2.45 nmol/L. Men with DHT concentrations below 0.59 nmol/L had increased risk for incident CVD events. Limitations: Observational study design, heterogeneity among studies, and imputation of missing data. Conclusion: Men with low testosterone, high LH, or very low estradiol concentrations had increased all-cause mortality. SHBG concentration was positively associated and DHT concentration was nonlinearly associated with all-cause and CVD mortality. Primary Funding Source: Medical Research Future Fund, Government of Western Australia, and Lawley Pharmaceuticals. (PROSPERO: CRD42019139668) [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
50. Testosterone, incretins and improving cardiometabolic health: An endocrinologist's perspective.
- Author
-
YEAP, BU B.
- Subjects
- *
TESTOSTERONE , *ENDOCRINOLOGISTS , *LEAN body mass , *INCRETINS , *TYPE 2 diabetes - Abstract
Testosterone, an anabolic hormone, can prevent or revert type 2 diabetes in men at high risk. Incretinbased weight-loss therapy is effective in both men and women, but reduces lean mass, as well as fat mass. Exercise may be the vital ingredient for preserving muscle and improving cardiometabolic health. [ABSTRACT FROM AUTHOR]
- Published
- 2024
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.